Welcome to our dedicated page for Visionary Holdings news (Ticker: GV), a resource for investors and traders seeking the latest updates and insights on Visionary Holdings stock.
Visionary Holdings Inc. (Nasdaq: GV) generates news at the intersection of education, health management, anti-aging medical aesthetics, and regenerative medicine. Company announcements describe an ongoing strategic transformation from a traditional education- and real estate-focused business toward a diversified platform centered on high-end medical aesthetics and big health technology, with AI-enabled education remaining as a supplementary division.
News coverage for GV includes updates on its fiscal year 2025 annual report, where the company outlined progress in its business restructuring and reported initial revenue contributions from emerging health-related businesses. Releases also detail Visionary Holdings' focus on health management initiatives, including gastrointestinal health management and early-stage commercialization efforts in Asia.
Another key stream of news relates to regenerative medicine and stem cell technology. Visionary Holdings has reported a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd., the creation of Visionary Yike Stemcell Technologies Inc. in Canada, and the launch of a stem cell-based anti-aging product line through its Visionary Health Technology Group Limited subsidiary. These items highlight the company’s emphasis on stem cell therapy, cellular rejuvenation, and premium anti-aging offerings in Asian markets.
Governance and compliance developments are also prominent in GV’s news. The company has announced board renewal, the formation of specialized committees, leadership changes, and auditor appointments, as well as a Nasdaq notification regarding a delayed Form 20-F filing and its plan to regain compliance. Additional releases describe Visionary Holdings’ controlling stake in a joint venture focused on Traditional Chinese Medicine health preservation.
Investors and observers reviewing GV news can expect updates on strategic partnerships, joint ventures, product launches in anti-aging and regenerative medicine, governance changes, and disclosures related to its education and health businesses.
Visionary Holdings (NASDAQ: GV) signed an Investment Cooperation Agreement for a proposed US$20 million strategic investment to advance a Qingdao anti-aging project in Qingdao West Coast New Area, China. The plan calls for a project company, a GV China Anti-Aging Research Center, and a GV Anti-Aging Health Management Center chain.
The investor intends to invest no less than US$20 million in two phases, with an initial milestone-based phase (payments of 30%/40%/30%) and a contemplated second-phase US$10 million. Progress remains subject to definitive agreements, due diligence, regulatory steps, and customary closing conditions.
Visionary Holdings (NASDAQ: GV) entered a strategic cooperation agreement with Zhejiang Chushanji Digital Technology to expand distribution of its V-series anti-aging products in China.
Chushanji operates an offline network across 5 provinces and ~10,000 stores. Visionary projects a preliminary potential annual revenue range of $10M–$15M, but notes the collaboration is at an initial stage and outcomes are uncertain due to market, execution, channel, and regulatory risks.
Visionary Holdings (NASDAQ: GV) announced a US$12 million exclusive distribution agreement with Huajin China for its flagship Premier Regenerative Complex – President Super Injection, targeting minimum contracted sales within 12 months. The Board approved a divestiture of 100% equity in Visionary Education Services & Management, refocusing the company on medical aesthetics and biotechnology.
Revenue recognition is subject to delivery, customer acceptance, and accounting standards. The company said the moves accelerate commercialization and concentrate capital and management on high-margin regenerative aesthetic products.
Visionary Holdings (NASDAQ: GV) provided a 2026–2027 business outlook, emphasizing a strategic shift into higher‑margin healthcare services and medical aesthetics. Management said commercialization of the RAMU anti‑aging product line could potentially reach approximately US$30 million in annual sales, subject to market conditions, regulatory approvals, and execution.
The company plans continued expansion into North America and Europe via product commercialization, distribution partnerships, and healthcare service collaborations, and intends to develop an integrated healthcare services platform combining products, wellness services, and biotechnology.
Visionary Holdings (NASDAQ: GV) signed an exclusive distribution agreement with Huajin China for its Premier Regenerative Complex – President Super Injection, establishing a minimum contracted sales target of US$12 million within 12 months.
On February 27, 2026, the Board approved divestiture of its education business, refocusing the company on medical aesthetics, anti-aging injectables, and biotechnology-driven healthcare.
Visionary Holdings (NASDAQ: GV) said its subsidiary GV Hong Kong is executing a previously signed commercial sales agreement with a total contract value of approximately US$9 million (signed September 2025).
Early-stage service activities are underway and the company expects further substantive execution milestones by the end of the first quarter of 2026, with revenue recognition and cash collection following contractual terms and applicable accounting standards.
Visionary Holdings (Nasdaq: GV) announced that its subsidiary Visionary Health Technology Group established three wholly owned regional subsidiaries in Qingdao, Wuxi and Wuhu on Feb. 18, 2026 to drive localized commercial expansion for regenerative medicine, cellular rejuvenation and aesthetic treatment products.
The move builds on GV’s Asia headquarters in Hangzhou and sales entity in Nanjing, creating a multi-city commercialization network to support localized sales teams, institutional partnerships, product deployment, and improved revenue visibility.
Visionary Holdings (NASDAQ: GV) entered a December 2025 private placement, issuing a $500,000 senior secured convertible promissory note for $450,000 gross proceeds. The note matures on December 11, 2026, accrues interest at the greater of prime+4.5% or 9% (semi‑annual payments) and jumps to 18% on default.
The note is convertible at the investor’s option into common stock at $1.44 per share, subject to Nasdaq rules and customary adjustments; terms update and differ from the prior January 31, 2025 note (principal $1,500,000; conversion price $2.25).
Visionary Holdings (Nasdaq: GV) announced Nasdaq has closed a listing deficiency after the company filed its Annual Report on Form 20-F for the year ended March 31, 2025.
Visionary filed the Form 20-F on January 28, 2026; Nasdaq issued a compliance confirmation on January 29, 2026, confirming continued listing and closure of the matter.
Visionary Holdings (Nasdaq: GV) regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Annual Report on Form 20-F for the fiscal year ended March 31, 2025.
The company filed the Form 20-F on January 28, 2026, and Nasdaq advised on January 29, 2026 that the matter is closed. Visionary reiterated its commitment to maintaining full compliance with Nasdaq listing standards and U.S. securities laws.